Knockin of mutant PIK3CA activates multiple oncogenic pathways

0301 basic medicine 0303 health sciences Glycogen Synthase Kinase 3 beta Class I Phosphatidylinositol 3-Kinases TOR Serine-Threonine Kinases Mice, Nude Breast Neoplasms Oncogenes 3. Good health Glycogen Synthase Kinase 3 Mice Phosphatidylinositol 3-Kinases 03 medical and health sciences Cell Line, Tumor Mutation Animals Humans Gene Knock-In Techniques Phosphorylation Colorectal Neoplasms Extracellular Signal-Regulated MAP Kinases Mammary Glands, Human Protein Kinases Proto-Oncogene Proteins c-akt
DOI: 10.1073/pnas.0813351106 Publication Date: 2009-02-07T05:06:11Z
ABSTRACT
The phosphatidylinositol 3-kinase subunit PIK3CA is frequently mutated in human cancers. Here we used gene targeting to "knock in" mutations into breast epithelial cells identify new therapeutic targets associated with oncogenic PIK3CA. Mutant knockin were capable of epidermal growth factor and mTOR-independent cell proliferation that was AKT, ERK, GSK3beta phosphorylation. Paradoxically, the inhibitors lithium chloride SB216763 selectively decreased colorectal cancer lines led a decrease target CYCLIN D1. Oral treatment preferentially inhibited nude mouse xenografts HCT-116 colon mutant compared isogenic knockout containing only wild-type Our findings suggest an important effector PIK3CA, lithium, FDA-approved therapy for bipolar disorders, has selective antineoplastic properties against cancers harbor these mutations.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (35)
CITATIONS (142)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....